PDGFRA and gastrointestinal stromal tumor: Further research is required incorporating larger sample sizes of GIST patients with the KIT, WT, and PDGFRA mutations, a longer follow-up, and different dosages of sunitinib or preimatinib in diverse GIST genotypes.